Welcome to our dedicated page for Virax Biolabs Group news (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group stock.
Virax Biolabs Group Limited reports developments in immunology research and diagnostics, with a focus on immune response detection and post-acute infection syndromes. Company updates center on the in-development ViraxImmune T cell immune-profiling platform, PAIS-related conditions such as Long COVID, post-treatment Lyme disease and ME/CFS, and the ImmuneSelect research-use-only product portfolio.
Recurring news themes include clinical study activity, research collaborations, regulatory and quality-system preparation, commercial planning for immune-profiling products, private placements and other capital-structure actions. Updates also cover board composition, shareholder communications and Nasdaq listing-compliance matters for the company’s ordinary shares.
Virax Biolabs (NASDAQ: VRAX) reported positive early pilot data for ViraxImmune™, a blood-based test in development for Long COVID, ME/CFS and related post-acute infection syndromes.
In more than 120 UK subjects, ViraxImmune™ showed separation between patients and healthy controls, with 88% specificity and 92% positive predictive value (PPV). Virax plans a larger clinical validation using 300 additional samples, with analysis expected to start in Q4 2026 and results in Q1 2027.
According to Virax, up to 21 million US adults may live with Long COVID and related PAIS, with 2.5 million new cases annually. The company is pursuing an initial U.S. LDT route followed by broader IVD development. ViraxImmune™ remains in development and is not approved for diagnostic use.
Virax Biolabs (NASDAQ: VRAX) outlined a focused 90–180 day plan centered on advancing ViraxImmune™ for post-acute infection syndromes (PAIS) and pursuing a U.S. Laboratory Developed Test (LDT) market-entry pathway.
Key facts: UK PAIS studies fully recruited, FDA pre-submission Q-Sub completed, Emory clinical planning under way, ISO 13485 and ISO 9001 certified, and management expects ~$6.4M cash at March 31, 2026 versus ~$2.6M market cap (April 10, 2026).
Virax Biolabs (NASDAQ: VRAX) achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system, issued by LRQA on 18 February 2026 and expiring 17 February 2029.
The company says the certifications support regulated IVD development readiness, U.S. clinical validation of ViraxImmune™, and evaluation of potential U.S. lab-based testing pathways including an LDT route.
Virax Biolabs Group (Nasdaq: VRAX) closed a private placement raising $5.0 million gross proceeds by issuing 12,500,000 ordinary shares (or equivalents) and preferred investment options to buy up to 12,500,000 ordinary shares at a combined price of $0.3999 per pre-funded warrant plus preferred option.
The pre-funded warrants are exercisable immediately at $0.0001 (no expiry). Preferred investment options are exercisable at $0.40 per share for five years from the effective date of a required registration statement. H.C. Wainwright acted as placement agent.
Net proceeds are intended for general working capital and are expected to extend cash runway into H1 2028, beyond planned completion and regulatory submissions for ViraxImmune US PASC study (FDA) and UK PAIS study (MHRA). The company agreed to register the resale of issued securities and to reduce and extend earlier preferred option terms (exercise price from $2.934 to $0.40 and extended term).
Virax Biolabs Group (Nasdaq: VRAX) announced a private placement to raise gross proceeds of approximately $5.0 million through the sale of 12,500,000 ordinary shares (or equivalents) and associated preferred investment options at $0.40 per share. The preferred investment options are exercisable immediately for five years from the effective date of an Initial Registration Statement. Closing is expected on or about December 4, 2025, subject to customary conditions. H.C. Wainwright is the exclusive placement agent. The company said net proceeds will be used for working capital and general corporate purposes. Virax agreed to file and seek effectiveness of a resale registration statement for the issued securities within specified timing and to repricing/extend prior Series A and B preferred options to the same terms.
Virax Biolabs (NASDAQ: VRAX) reported clinical and operational progress and outlined 2026 priorities focused on its ViraxImmune™ T cell diagnostic programme for post-acute infection syndromes (PAIS).
Key facts: full recruitment completed in UK study VRX-002 (160 participants) with initial data expected in Q2 2026; second UK study VRX-003 fully enrolled (100 subjects); U.S. research collaboration with Emory University to support a planned U.S. study; ongoing expansion of the ImmuneSelect RUO product portfolio for near-term research revenue; and a debt-free balance sheet with $3.3M cash, total assets of $5.7M, liabilities of $0.6M and market capitalization of ~$1.7M.
Virax Biolabs (NASDAQ: VRAX) completed full UK recruitment for its multi-centre study of the ViraxImmune™ T cell assay in Post-Acute Infection Syndromes (PAIS), reaching the target of 160 participants in a 3:1 randomised design with 40 symptomatic patients each for Long COVID, PTLD, and ME/CFS. Clinical samples will undergo immunological analysis to evaluate assay performance to support UK regulatory filings with the MHRA and inform potential U.S. submissions.
Virax also received constructive FDA feedback from a Sept 10, 2025 pre-submission meeting and plans a U.S. clinical study with Emory University in 2026. Initial readouts are expected in Q2 2026.
Virax Biolabs (NASDAQ:VRAX) has entered into a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™, focusing on immune profiling in post-viral syndromes, particularly long COVID (PASC).
The company is preparing for a pre-submission meeting with the FDA in early September 2025 to discuss ViraxImmune™'s regulatory pathway and intended use. Emory's Laboratory for Innovative Assay Development (ELIAD) will handle patient recruitment, testing, and analysis to generate clinical data supporting regulatory submissions.
ViraxImmune™ is a T cell testing technology that evaluates patient immune response profiles, offering potential advantages over traditional antibody testing for diagnosing chronic and post-viral conditions.
Virax Biolabs (NASDAQ:VRAX), a biotechnology company specializing in viral disease diagnostics, has appointed Dr. Iain Miller as an Independent Director effective July 29, 2025. Dr. Miller, who replaces outgoing director Yair Erez, brings over 30 years of leadership experience in diagnostics and MedTech sectors.
Dr. Miller's extensive background includes senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has founded four MedTech companies and served as CEO of Presymptom Health, where he developed InfectiClear®. His expertise spans commercial, technical, and regulatory domains, with experience serving on the UK's NICE Technology Appraisal Committee and contributing to NHS England and MHRA innovation programs.
Virax Biolabs (NASDAQ: VRAX) has received a notification from Nasdaq on July 14, 2025, regarding non-compliance with the minimum bid price requirement. The company's stock has traded below the required $1.00 minimum bid price for 30 consecutive business days.
The biotechnology company has been granted a 180-day compliance period until January 12, 2026, to regain compliance. Virax can achieve compliance if its stock maintains a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Meanwhile, VRAX shares will continue trading on Nasdaq without interruption.